Impact of COVID-19 on percutaneous coronary intervention utilization and mortality in New York.
Edward L HannanYe ZhongKimberly CozzensAlda OsinagaLinda EfferenAlice K JacobsFrederick S K LingWalford GaryFerdinand J VendittiPeter B BergerJacqueline Tamis-HollandSpencer B KingPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023)
There were large decreases in the utilization of PCI during COVID-19, with the percentage of decrease being highly sensitive to patient acuity. By the second quarter of 2021, prepandemic volumes were nearly restored for all patient subgroups. Very few PCI patients had current COVID-19 throughout the pandemic period, but the number of PCI patients with a COVID-19 history increased steadily during the pandemic. PCI patients with COVID-19 accompanied by ARDS were at much higher risk of short-term mortality than patients who never had COVID-19. COVID-19 without ARDS and history of COVID-19 were not associated with higher mortality for PCI patients as of the second quarter of 2021.
Keyphrases
- coronavirus disease
- sars cov
- percutaneous coronary intervention
- coronary artery disease
- acute coronary syndrome
- acute myocardial infarction
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- end stage renal disease
- respiratory syndrome coronavirus
- cardiovascular events
- ejection fraction
- coronary artery bypass grafting
- newly diagnosed
- chronic kidney disease
- acute respiratory distress syndrome
- heart failure
- patient reported outcomes
- prognostic factors
- intensive care unit
- risk factors
- type diabetes
- peritoneal dialysis
- cardiovascular disease
- coronary artery bypass
- high resolution